Christopher Clarke, MD
Pulmonary Disease · Fairhope, ALNPI 1013336940
Payments from drug & device makers
Across 189 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$765
- Regeneron Healthcare Solutions, Inc.$433
- GSK$354
- Electromed, Inc.$311
- AstraZeneca$248
- Sanofi$197
- plus $900 from 23 others
What the payments were for
- Food & beverage$3,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 51 | $765 |
| Regeneron Healthcare Solutions, Inc. | 20 | $433 |
| GSK | 26 | $354 |
| Electromed, Inc. | 18 | $311 |
| AstraZeneca(2 entities) | 14 | $248 |
| Sanofi | 9 | $197 |
| Verona Pharma, Inc. | 5 | $109 |
| Pfizer | 6 | $74 |
| Mylan Specialty L.p. | 4 | $68 |
| Amgen | 4 | $52 |
| Gilead | 3 | $48 |
| Lilly USA, LLC | 3 | $47 |
| Mannkind Corporation | 3 | $45 |
| Viatris Specialty LLC | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Novo Nordisk | 3 | $38 |
| Insmed, Inc. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| BETA Bionics, Inc. | 1 | $31 |
| AbbVie | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $14 |
How this compares
$3,208 in reported general payments places this provider in the 45th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 217 | $197,918 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 177 | $127,738 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $32,800 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $17,509 |
| Spiriva RespimatTiotropium Bromide | 24 | $12,144 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $5,349 |
| Montelukast Sodium | 377 | $3,255 |
| Clotrimazole | 84 | $2,487 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,485 |
| Fluconazole | 150 | $1,178 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 91 | $1,173 |
| Ventolin HfaAlbuterol Sulfate | 11 | $858 |
| Prednisone | 242 | $697 |
| Omeprazole | 60 | $521 |
| Fluticasone Propionate | 22 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $354 | $215,427250 claims |
| AstraZenecaBreztri Aerosphere | $248 | $127,738177 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $765 | $44,94473 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Fairhope
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.